Immunophilins: Their Properties and Their Potential Role in Therapeutic Drug Monitoring
- 1 February 2000
- journal article
- review article
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 22 (1) , 44-46
- https://doi.org/10.1097/00007691-200002000-00009
Abstract
This article reviews recent developments in the immunophilin arena and the current state of knowledge about the biochemical properties of immunophilins. The role of immunophilin-binding assays is also explored with the conclusion that some of these immunosuppressive-drug–binding proteins may provide better assays for sirolimus and tacrolimus than current immunoassays.Keywords
This publication has 15 references indexed in Scilit:
- Cyclosporine Metabolite Cross-Reactivity in Different Cyclosporine AssaysClinical Biochemistry, 1998
- Radioreceptor Assay for Sirolimus in Patients with Decreased Platelet CountsClinical Biochemistry, 1997
- The 37 kDa Immunophilin Has Uracil DNA Glycosylase But Not Rotamase ActivityClinical Biochemistry, 1997
- Identification of a 37 kDa Tacrolimus, Sirolimus and cyclosporine binding immunophilin possessing glyceraldehyde 3-phosphate dehydrogenase activity isolated from the JURKAT T cell lineClinical Biochemistry, 1997
- Radioreceptor assay for sirolimusClinical Biochemistry, 1996
- Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cellsBiochemical and Biophysical Research Communications, 1992
- Immunophilin ligands demonstrate common features of signal transduction leading to exocytosis or transcription.Proceedings of the National Academy of Sciences, 1991
- A receptor for the immuno-suppressant FK506 is a cis–trans peptidyl-prolyl isomeraseNature, 1989
- Improved receptor assay for measuring digoxin activity.Clinical Chemistry, 1988
- Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2European Journal of Immunology, 1981